REPORT DESCRIPTION The Asia-Pacific Hormone Replacement market is expected to rise with a largest potential. The major sector expected to grow largest in this market is Estrogen Administration with a CAGR of 2.8%. Hormone replacement therapy, is a means of replacing hormones that are no longer produced by the body. It basically refers to use of hormones-Estrogen and Progestin for alleviating symptoms associated with menopause.This replacement therapy may also protect against osteoporosis, coronary heart disease, and may also prevent or delay the onset of Alzheimer’s disease. Asia- pacific Hormone replacement therapy market is driven by increase in aged population, innovative drug delivery technologies, and huge scope in untapped Asian markets. Major constraints for market is high cost of treatment, bioidentical hormones and reimbursement issues associated with the market. The Global Hormone Replacement Therapy market is divided into three segments: Estrogen Replacement Therapy, Growth Hormone Replacement Therapy, and Thyroid Hormone Replacement. The market is segmented on the basis of Route of administration of the drug and also type of therapies covered under Hormone Replacement. Globally, Market is divided into different regions i.e India, China, Japan, ROA. Major Players like Actavis plc, Bayer AG, Merck & Co. Inc, Novartis AG, Novo Nordisk A/S are following strategies like mergers and acquisitions, new product launches, partnerships in order to keep pace with the market.
What makes our report unique? 1.The report provides in depth analysis of the market and forecasts future trends in HRT market based on the different therapies available in Hormone replacement Therapy. 2.We provide the longest segmentation of the market based on route of administration( Oral tablets, Implants, Patches, Vaginal Creams) and type of therapy( Estrogen replacement therapy, Progestin replacement therapy and Estrogen-Progestin replacement therapy) 3. High level analysis of various products available in the current market which comprises Estrogen products, Progestin products, and a combination therapy of Estrogen and Progestin.